User login
Key clinical point: Patients with plaque psoriasis were at risk of developing psoriatic arthritis (PsA) even if undergoing treatment with biologics; thus, screening for PsA at each follow-up visit should be strongly implemented.
Major finding: Overall, new-onset PsA developed in 8.5% of patients who were under treatment with any of the biologics including anti-tumor necrosis factor, anti-interleukin (IL)12/23, anti-IL17, and anti-IL23. No significant risk factors were identified for new-onset PsA.
Study details: Findings are from a 1-year prospective study including 118 patients with moderate-to-severe psoriasis without PsA who underwent treatment with biologics for at least 3 months.
Disclosures: This study did not receive any external funding. The authors declared no conflict of interests.
Source: Megna M et al. Biomedicines. 2021;9(10):1482 (Oct 15). Doi: 10.3390/biomedicines9101482.
Key clinical point: Patients with plaque psoriasis were at risk of developing psoriatic arthritis (PsA) even if undergoing treatment with biologics; thus, screening for PsA at each follow-up visit should be strongly implemented.
Major finding: Overall, new-onset PsA developed in 8.5% of patients who were under treatment with any of the biologics including anti-tumor necrosis factor, anti-interleukin (IL)12/23, anti-IL17, and anti-IL23. No significant risk factors were identified for new-onset PsA.
Study details: Findings are from a 1-year prospective study including 118 patients with moderate-to-severe psoriasis without PsA who underwent treatment with biologics for at least 3 months.
Disclosures: This study did not receive any external funding. The authors declared no conflict of interests.
Source: Megna M et al. Biomedicines. 2021;9(10):1482 (Oct 15). Doi: 10.3390/biomedicines9101482.
Key clinical point: Patients with plaque psoriasis were at risk of developing psoriatic arthritis (PsA) even if undergoing treatment with biologics; thus, screening for PsA at each follow-up visit should be strongly implemented.
Major finding: Overall, new-onset PsA developed in 8.5% of patients who were under treatment with any of the biologics including anti-tumor necrosis factor, anti-interleukin (IL)12/23, anti-IL17, and anti-IL23. No significant risk factors were identified for new-onset PsA.
Study details: Findings are from a 1-year prospective study including 118 patients with moderate-to-severe psoriasis without PsA who underwent treatment with biologics for at least 3 months.
Disclosures: This study did not receive any external funding. The authors declared no conflict of interests.
Source: Megna M et al. Biomedicines. 2021;9(10):1482 (Oct 15). Doi: 10.3390/biomedicines9101482.